Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, if he will make an assessment of whether individual ICBs are deviating from NICE guidance.

Integrated care boards are legally required to make funding available for medicines recommended in a National Institute for Health and Care Excellence (NICE) technology appraisal or highly specialised technology evaluation, normally within three months of the publication of final guidance. The effect of this legal obligation is that all NICE-approved treatments must be included in local formularies for use in line with NICE’s recommendations and with no additional funding or formulary restrictions.

As part of commitments made in the 2024 voluntary scheme for branded medicines pricing and access, NHS England is developing a local formulary national minimum dataset to increase visibility of local variation in the implementation of NICE guidance, identify where variation in local formularies may be creating barriers to access, and to provide assurance to NHS England when a NICE recommended treatment has been listed on a local formulary.